[{"from": "human", "value": "Describe this molecule. [C][C][C][N][Branch2][Ring1][Branch1][C][C][=N][N][=C][Branch1][=Branch1][N][Ring1][=Branch2][Ring1][Branch1][C][Branch1][C][F][Branch1][C][F][F][C][=Branch1][C][=O][C][=C][Branch2][Ring1][O][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][C][=N][N][C][=Branch1][C][=O][C][=C][C][=C][C][=C][Ring1][=Branch1][Ring1][O][F]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) 1 (PARP1) and 2 (PARP2), with potential antineoplastic activity. Upon oral administration, simmiparib selectively binds to PARP and prevents PARP-mediated DNA repair of breaks in single-stranded DNA via the base excision repair pathway. This induces the accumulation of DNA strand breaks, promotes genomic instability, induces G2/M arrest and leads to apoptosis. PARP is activated by single-strand DNA breaks and catalyzes post-translational ADP-ribosylation of nuclear proteins, which signal and recruit other proteins to repair damaged DNA."}]